Comments on: Jardiance® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes regardless of the type of cardiovascular disease at baseline

Comments on: Jardiance® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes regardless of the type of cardiovascular disease at baseline https://www.novumpr.nl/2016/11/14/jardiance-empagliflozin-consistently-reduced-the-risk-of-cardiovascular-death-in-adults-with-type-2-diabetes-regardless-of-the-type-of-cardiovascular-disease-at-baseline/?utm_source=rss&utm_medium=rss&utm_campaign=jardiance-empagliflozin-consistently-reduced-the-risk-of-cardiovascular-death-in-adults-with-type-2-diabetes-regardless-of-the-type-of-cardiovascular-disease-at-baseline NovumPR press releases Mon, 14 Nov 2016 09:03:55 +0000 hourly 1 https://wordpress.org/?v=6.8.3